Skocz do pozycji: 1.

Tytuł:

Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.

Autorzy:

Erfanpoor, Saeed (AUTHOR)
Banihashemi, Seyed Reza (AUTHOR)
Mokhbaeralsafa, Ladan (AUTHOR)
Kalantari, Saeed (AUTHOR)
Es-haghi, Ali (AUTHOR)
Nofeli, Mojtaba (AUTHOR)
Rezaei Mokarram, Ali (AUTHOR)
Sadeghi, Fariba (AUTHOR)
Hajimoradi, Monireh (AUTHOR)
Razaz, Seyad Hossein (AUTHOR)
Taghdiri, Maryam (AUTHOR)
Lotfi, Mohsen (AUTHOR)
Khorasani, Akbar (AUTHOR)
Ansarifar, Akram (AUTHOR)
Masoumi, Safdar (AUTHOR)
Mohazzab, Arash (AUTHOR)
Filsoof, Sara (AUTHOR)
Mohseni, Vahideh (AUTHOR)
Shahsavan, Masoumeh (AUTHOR)
Gharavi, Niloufar (AUTHOR)

Pokaż więcej

Źródło:

BMC Medicine. 2/20/2024, Vol. 22 Issue 1, p1-11. 11p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 2.

Tytuł:

Higher correlation between neutralizing antibodies and surrogate neutralizing or binding antibodies in COVID-19 patients than vaccine recipients.

Autorzy:

Lerdsamran H; Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Anusorntanawat R; Chaophraya Yommarat Hospital, Office of the Permanent Secretary, Ministry of Public Health, Suphanburi, Thailand.
Sangsiriwut K; Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Sawadpongpan S; Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Prasertsopon J; Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Thinpan N; Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Intalapaporn P; Department of Medical Services, Rajavithi Hospital, Ministry of Public Health, Bangkok, Thailand.
Techasuwanna R; Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Okada P; Department of Medical Science, Ministry of Public Health, Nonthaburi, Thailand.
Puthavathana P; Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2024 Apr 16; Vol. 19 (4), pp. e0298033. Date of Electronic Publication: 2024 Apr 16 (Print Publication: 2024).

Typ publikacji:

Journal Article

MeSH Terms:

COVID-19*
Vaccines*
Humans ; Antibodies, Neutralizing ; SARS-CoV-2 ; Antibodies, Viral ; Neutralization Tests

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 3.

Tytuł:

Longitudinal and Cross-Sectional Evaluation of Two Commercial Swine Breeding Herds to Characterize Neutralizing Antibody Levels following Porcine Epidemic Diarrhea Virus Outbreaks.

Autorzy:

Brown J; Swine Medicine Education Center, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
Skoland K; Swine Medicine Education Center, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
Kittrell H; Swine Medicine Education Center, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
Ellingson J; AMVC Management Services, Audubon, IA 50025, USA.
Thomas P; AMVC Management Services, Audubon, IA 50025, USA.
Ruston C; Swine Medicine Education Center, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
Baum D; Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
Karriker L; Swine Medicine Education Center, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.

Pokaż więcej

Źródło:

Viruses [Viruses] 2024 Feb 21; Vol. 16 (3). Date of Electronic Publication: 2024 Feb 21.

Typ publikacji:

Journal Article

MeSH Terms:

Porcine epidemic diarrhea virus*
Coronavirus Infections*/epidemiology
Coronavirus Infections*/veterinary
Swine Diseases*
Swine ; Animals ; Female ; Antibodies, Neutralizing ; Antibodies, Viral ; Neutralization Tests ; Cross-Sectional Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 4.

Tytuł:

The responsibility of thwarting and managing Japanese encephalitis cannot be understated—Outbreaks or resurgences may manifest, catching us off guard.

Autorzy:

Wang, Ran (AUTHOR)
Xie, Zhengde (AUTHOR)

Pokaż więcej

Źródło:

PLoS Neglected Tropical Diseases. 11/2/2023, Vol. 17 Issue 11, p1-4. 4p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 5.

Tytuł:

Differential laboratory passaging of SARS-CoV-2 viral stocks impacts the in vitro assessment of neutralizing antibodies.

Autorzy:

Avila-Herrera A; Lawrence Livermore National Laboratory, Computing Directorate, Global Security Computing Applications Division, Livermore, California, United States of America.
Kimbrel JA; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Manuel Martí J; Lawrence Livermore National Laboratory, Computing Directorate, Global Security Computing Applications Division, Livermore, California, United States of America.
Thissen J; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Saada EA; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Weisenberger T; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Arrildt KT; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Segelke BW; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Allen JE; Lawrence Livermore National Laboratory, Computing Directorate, Global Security Computing Applications Division, Livermore, California, United States of America.
Zemla A; Lawrence Livermore National Laboratory, Computing Directorate, Global Security Computing Applications Division, Livermore, California, United States of America.
Borucki MK; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2024 Jan 25; Vol. 19 (1), pp. e0289198. Date of Electronic Publication: 2024 Jan 25 (Print Publication: 2024).

Typ publikacji:

Journal Article

MeSH Terms:

Antibodies, Neutralizing*
COVID-19*
Humans ; SARS-CoV-2/genetics ; Antibodies, Viral ; Neutralization Tests ; Immune Sera ; Spike Glycoprotein, Coronavirus/genetics

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 6.

Tytuł:

Multicentric evaluation of sensitivity of eight commercial anti-SARS-CoV-2 antibody assays and their correlation to virus neutralization titers in seropositive subjects.

Autorzy:

Fajfr M; Institute of Clinical Microbiology, University Hospital in Hradec Kralove, Sokolska 581, Hradec Kralove, 50005, Czech Republic.; Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
Pajer P; Military Health Institute, Prague, Czech Republic.
Ruzek D; Department of Virology, Veterinary Research Institute, Brno, Czech Republic.; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic.; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
Sleha R; Department of Epidemiology, Military Faculty of Medicine, University of Defence, Hradec Kralove, Czech Republic.
Janovska S; Department of Epidemiology, Military Faculty of Medicine, University of Defence, Hradec Kralove, Czech Republic.
Bohonek M; Department of Hematology and Blood Transfusion, Military University Hospital Prague, Praha, Czech Republic.; Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic.
Kabickova H; Military Health Institute, Prague, Czech Republic.
Kubicková P; Military Health Institute, Prague, Czech Republic.
Stefanik M; Department of Virology, Veterinary Research Institute, Brno, Czech Republic.; Department of Hematology and Blood Transfusion, Military University Hospital Prague, Praha, Czech Republic.
Strakova P; Department of Virology, Veterinary Research Institute, Brno, Czech Republic.; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic.; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
Bostik P; Institute of Clinical Microbiology, University Hospital in Hradec Kralove, Sokolska 581, Hradec Kralove, 50005, Czech Republic. .; Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Jan 16; Vol. 14 (1), pp. 1421. Date of Electronic Publication: 2024 Jan 16.

Typ publikacji:

Journal Article

MeSH Terms:

SARS-CoV-2*
COVID-19*/diagnosis
Humans ; Serologic Tests/methods ; Sensitivity and Specificity ; Antibodies, Viral ; Immunoglobulin G ; Neutralization Tests/methods ; Antibodies, Neutralizing

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 7.

Tytuł:

Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States.

Autorzy:

Wieczorek L; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Sanders-Buell E; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Zemil M; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Lewitus E; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Kavusak E; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Heller J; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Molnar S; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Rao M; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Smith G; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Bose M; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Nguyen A; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Dhungana A; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Okada K; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Parisi K; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Silas D; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Slike B; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Ganesan A; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.; Walter Reed National Military Medical Center, Bethesda, Maryland, United States of America.
Okulicz J; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.; Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, United States of America.
Lalani T; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.; Naval Medical Center Portsmouth, Portsmouth, Virginia, United States of America.
Agan BK; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Crowell TA; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Darden J; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.; Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Rolland M; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Vasan S; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Ake J; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Krebs SJ; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Peel S; Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Tovanabutra S; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Polonis VR; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.

Pokaż więcej

Źródło:

PLoS pathogens [PLoS Pathog] 2023 Dec 06; Vol. 19 (12), pp. e1011780. Date of Electronic Publication: 2023 Dec 06 (Print Publication: 2023).

Typ publikacji:

Meta-Analysis; Journal Article

MeSH Terms:

HIV Infections*
HIV-1*/genetics
HIV Seropositivity*
Humans ; United States/epidemiology ; HIV Antibodies ; Neutralization Tests ; env Gene Products, Human Immunodeficiency Virus/genetics ; Antibodies, Neutralizing ; Pandemics

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 8.

Tytuł:

Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants.

Autorzy:

Ko HL; Division of Research Program, Scripps Korea Antibody Institute, Chuncheon, 24341, Republic of Korea.; Department of Microbiology, College of Medical Science, Kangwon National University, Chuncheon-si, Gangwon-do, 24341, South Korea.
Lee DK; Division of Research Program, Scripps Korea Antibody Institute, Chuncheon, 24341, Republic of Korea.; Department of Microbiology, College of Medical Science, Kangwon National University, Chuncheon-si, Gangwon-do, 24341, South Korea.
Kim Y; Division of Research Program, Scripps Korea Antibody Institute, Chuncheon, 24341, Republic of Korea.; Department of Microbiology, College of Medical Science, Kangwon National University, Chuncheon-si, Gangwon-do, 24341, South Korea.
Jang HJ; Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, South Korea.
Lee YW; Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, South Korea.
Lee HY; Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, South Korea.
Seok SH; Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon-si, Gangwon-do, 24341, South Korea.
Park JW; Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon-si, Gangwon-do, 24341, South Korea.
Limb JK; Korea Mouse Phenotyping Center (KMPC), Seoul National University, Seoul, 08826, South Korea.
On DI; Korea Mouse Phenotyping Center (KMPC), Seoul National University, Seoul, 08826, South Korea.; Laboratory of Developmental Biology and Genomics, Research Institute for Veterinary Science, and BK21 Program for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, 08826, South Korea.
Yun JW; Laboratory of Veterinary Toxicology, College of Veterinary Medicine, Seoul National University, Seoul, 08826, South Korea.
Lyoo KS; College of Veterinary Medicine, Jeonbuk National University, Iksan, 54596, Republic of Korea.
Song D; Department of Veterinary Medicine Virology Laboratory, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.
Yeom M; Department of Veterinary Medicine Virology Laboratory, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.
Lee H; Department of Veterinary Medicine Virology Laboratory, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.
Seong JK; Korea Mouse Phenotyping Center (KMPC), Seoul National University, Seoul, 08826, South Korea. .; Laboratory of Developmental Biology and Genomics, Research Institute for Veterinary Science, and BK21 Program for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, 08826, South Korea. .; Interdisciplinary Program for Bioinformatics, Program for Cancer Biology and BIO-MAX/N-Bio Institute, Seoul National University, Seoul, 08826, South Korea. .
Lee S; Division of Research Program, Scripps Korea Antibody Institute, Chuncheon, 24341, Republic of Korea. .

Pokaż więcej

Źródło:

Virology journal [Virol J] 2023 Dec 01; Vol. 20 (1), pp. 285. Date of Electronic Publication: 2023 Dec 01.

Typ publikacji:

Journal Article

MeSH Terms:

SARS-CoV-2*/genetics
COVID-19*
Humans ; Antibodies, Monoclonal ; Neutralization Tests ; Receptors, Virus/metabolism ; Antibodies, Neutralizing ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus/chemistry

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 9.

Tytuł:

Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening.

Autorzy:

O'Reilly S; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
Kenny G; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.; Department of Infectious Diseases, St Vincent's University Hospital, Elm Park, Dublin, Ireland.
Alrawahneh T; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
Francois N; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
Gu L; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
Angeliadis M; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
de Masson d'Autume V; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
Garcia Leon A; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
Feeney ER; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.; Department of Infectious Diseases, St Vincent's University Hospital, Elm Park, Dublin, Ireland.
Yousif O; Endocrinology Department, Wexford General Hospital, Carricklawn, Wexford, Ireland.
Cotter A; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.; Department of Infectious Diseases, Mater Misericordiae University Hospital, Eccles St, Dublin, Ireland.
de Barra E; Department of Infectious Diseases, Beaumont Hospital, Beaumont, Dublin, Ireland.; Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Horgan M; Department of Infectious Diseases, Cork University Hospital, Wilton, Cork, Ireland.
Mallon PWG; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.; Department of Infectious Diseases, St Vincent's University Hospital, Elm Park, Dublin, Ireland.
Gautier V; Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin, Ireland.; School of Medicine, University College Dublin, Belfield, Dublin, Ireland.; Conway Institute of Biomedical and Biomolecular Research, University College Dublin, Belfield, Dublin 4, Ireland.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2023 Nov 30; Vol. 18 (11), pp. e0294262. Date of Electronic Publication: 2023 Nov 30 (Print Publication: 2023).

Typ publikacji:

Journal Article

MeSH Terms:

COVID-19*
Vaccines*
Humans ; Flow Cytometry ; SARS-CoV-2 ; Neutralization Tests ; Antibodies, Neutralizing ; Antibodies, Viral

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 10.

Tytuł:

Neutralizing Antibody Response to Genotypically Diverse Measles Viruses in Clinically Suspected Measles Cases.

Autorzy:

Vaidya SR; ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.
Kumbhar NS; ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.
Andhare GK; ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.
Pawar N; ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.
Walimbe AM; ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.
Kinikar M; Bioinformatics Centre, Savitribai Phule Pune University, Pune 411007, India.
Kasibhatla SM; Bioinformatics Centre, Savitribai Phule Pune University, Pune 411007, India.; HPC-Medical and Bioinformatics Applications Group, Centre for Development of Advanced Computing, Panchavati, Pashan, Pune 411008, India.
Kulkarni-Kale U; Bioinformatics Centre, Savitribai Phule Pune University, Pune 411007, India.

Pokaż więcej

Źródło:

Viruses [Viruses] 2023 Nov 10; Vol. 15 (11). Date of Electronic Publication: 2023 Nov 10.

Typ publikacji:

Journal Article

MeSH Terms:

Antibodies, Neutralizing*
Measles*
Humans ; Antibodies, Viral ; Neutralization Tests ; Measles virus/genetics ; Measles Vaccine ; Epitopes ; Immunoglobulin M

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 11.

Tytuł:

Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern.

Autorzy:

Santos da Silva, Eveline (AUTHOR)
Servais, Jean-Yves (AUTHOR)
Kohnen, Michel (AUTHOR)
Arendt, Vic (AUTHOR)
Staub, Therese (AUTHOR)
Krüger, Rejko (AUTHOR)
Fagherazzi, Guy (AUTHOR)
Wilmes, Paul (AUTHOR)
Hübschen, Judith M. (AUTHOR)
Ollert, Markus (AUTHOR)
Perez-Bercoff, Danielle (AUTHOR)
Seguin-Devaux, Carole (AUTHOR)

Pokaż więcej

Źródło:

International Journal of Molecular Sciences. Oct2023, Vol. 24 Issue 19, p14965. 19p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 12.

Tytuł:

Body Temperature Drop as a Humane Endpoint in Snake Venom-Lethality Neutralization Tests.

Autorzy:

De Jesus, Rosa (AUTHOR)
Tratner, Adam E. (AUTHOR)
Madrid, Alanna (AUTHOR)
Rivera-Mondragón, Andrés (AUTHOR)
Navas, Goy E. (AUTHOR)
Lleonart, Ricardo (AUTHOR)
Britton, Gabrielle B. (AUTHOR)
Fernández, Patricia L. (AUTHOR)

Pokaż więcej

Źródło:

Toxins. Sep2023, Vol. 15 Issue 9, p525. 12p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 13.

Tytuł:

Development of a Cell-Based SARS-CoV-2 Pseudovirus Neutralization Assay Using Imaging and Flow Cytometry Analysis.

Autorzy:

Izac JR; Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD 20899, USA.
Kwee EJ; Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD 20899, USA.
Tian L; Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD 20899, USA.
Elsheikh E; Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD 20899, USA.
Gaigalas AK; Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD 20899, USA.
Elliott JT; Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD 20899, USA.
Wang L; Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD 20899, USA.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2023 Aug 02; Vol. 24 (15). Date of Electronic Publication: 2023 Aug 02.

Typ publikacji:

Journal Article

MeSH Terms:

SARS-CoV-2*
COVID-19*
Humans ; Flow Cytometry ; Antibodies, Viral ; Neutralization Tests/methods ; Antibodies, Neutralizing

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 14.

Tytuł:

SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.

Autorzy:

Kay GA; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.; Departments of Vector Biology and Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK.
Owen SI; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Giorgi E; Centre for Health Informatics Computing and Statistics, Lancaster University Medical School, Lancaster University, Lancaster, UK.
Clark DJ; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Williams CT; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Menzies S; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Cuevas LE; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Davies BMO; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Eckersley NM; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Hughes GL; Departments of Vector Biology and Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK.
Kirwan DE; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Krishna S; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.; St George's University Hospitals NHS Foundation Trust, London, UK.; Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany.; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Patterson EI; Departments of Vector Biology and Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK.; Department of Biological Sciences, Brock University, St. Catharines, Canada.
Planche T; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.; St George's University Hospitals NHS Foundation Trust, London, UK.
Staines HM; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK. .
Adams ER; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2022 Mar 01; Vol. 12 (1), pp. 3351. Date of Electronic Publication: 2022 Mar 01.

Typ publikacji:

Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Neutralization Tests*
Antibodies, Viral/*immunology
COVID-19/*immunology
Immunoglobulin G/*immunology
Immunoglobulin M/*immunology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Aged ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Male ; Middle Aged

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 15.

Tytuł:

Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.

Autorzy:

Bassi J; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Pertusini L; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Hitz P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Terrot T; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Franzosi Y; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Muoio F; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Saliba C; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Meury M; Vir Biotechnology, San Francisco, California, United States of America.
Dellota EA Jr; Vir Biotechnology, San Francisco, California, United States of America.
Dillen JR; Vir Biotechnology, San Francisco, California, United States of America.
Hernandez P; Vir Biotechnology, San Francisco, California, United States of America.
Czudnochowski N; Vir Biotechnology, San Francisco, California, United States of America.
Cameroni E; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Beria N; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Ventresca M; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Badellino A; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Lavorato-Hadjeres S; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Lecchi E; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Bonora T; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Mattiolo M; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Trinci G; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Garzoni D; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Bonforte G; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Forni-Ogna V; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Giunzioni D; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Berwert L; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, United Kingdom.; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, Australia.
Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Science of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.
Cippà P; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Corti D; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Lanzavecchia A; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Piccoli L; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2022 Feb 10; Vol. 17 (2), pp. e0263328. Date of Electronic Publication: 2022 Feb 10 (Print Publication: 2022).

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Neutralization Tests*
Renal Dialysis*
Vaccination*
Antibodies, Neutralizing/*immunology
SARS-CoV-2/*immunology
Animals ; Antibodies, Neutralizing/blood ; Antibody Affinity ; CHO Cells ; COVID-19 Vaccines/immunology ; Case-Control Studies ; Cricetulus ; Dose-Response Relationship, Immunologic ; Follow-Up Studies ; HEK293 Cells ; Humans ; Immunoglobulin G/blood ; Risk Factors ; mRNA Vaccines/immunology

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 16.

Tytuł:

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.

Autorzy:

Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. .; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. .; Department of Global Health, University of Washington, Seattle, WA, USA. .
Borisov O; Biomedical Advanced Research and Development Authority, Washington, DC, USA.
Kee JJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Wrin T; LabCorp-Monogram Biosciences, South San Francisco, CA, USA.
Cai S; LabCorp-Monogram Biosciences, South San Francisco, CA, USA.
Sarzotti-Kelsoe M; Department of Surgery, Duke University Medical Center, Durham, NC, USA.; Department of Immunology, Duke University Medical Center, Durham, NC, USA.
McDanal C; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Eaton A; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Pajon R; Moderna, Inc., Cambridge, MA, USA.
Hural J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Posavad CM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gill K; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Karuna S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Departments of Medicine and Laboratory Medicine, University of Washington, Seattle, WA, USA.
Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Biostatistics, University of Washington, Seattle, WA, USA.
Petropoulos CJ; LabCorp-Monogram Biosciences, South San Francisco, CA, USA.
Montefiori DC; Department of Surgery, Duke University Medical Center, Durham, NC, USA. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2021 Dec 14; Vol. 11 (1), pp. 23921. Date of Electronic Publication: 2021 Dec 14.

Typ publikacji:

Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

MeSH Terms:

Antibodies, Neutralizing/*blood
COVID-19/*immunology
Neutralization Tests/*standards
SARS-CoV-2/*immunology
2019-nCoV Vaccine mRNA-1273/immunology ; Antibodies, Viral/blood ; COVID-19/blood ; Clinical Decision-Making ; Clinical Trials as Topic ; Diagnostic Tests, Routine ; Humans ; Neutralization Tests/methods ; World Health Organization

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 17.

Tytuł:

Detection of SARS-CoV-2 Antibodies: Comparison of Enzyme Immunoassay, Surrogate Neutralization and Virus Neutralization Test.

Autorzy:

Vilibic-Cavlek, Tatjana (AUTHOR)
Bogdanic, Maja (AUTHOR)
Borko, Ema (AUTHOR)
Hruskar, Zeljka (AUTHOR)
Zilic, Denis (AUTHOR)
Ferenc, Thomas (AUTHOR)
Tabain, Irena (AUTHOR)
Barbic, Ljubo (AUTHOR)
Vujica Ferenc, Mateja (AUTHOR)
Ferencak, Ivana (AUTHOR)
Stevanovic, Vladimir (AUTHOR)

Pokaż więcej

Źródło:

Antibodies (2073-4468). Jun2023, Vol. 12 Issue 2, p35. 9p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 18.

Tytuł:

Comparison of measles IgG enzyme immunoassays (EIA) versus plaque reduction neutralization test (PRNT) for measuring measles serostatus: a systematic review of head-to-head analyses of measles IgG EIA and PRNT.

Autorzy:

Lutz, Chelsea S. (AUTHOR)
Hasan, Alvira Z. (AUTHOR)
Bolotin, Shelly (AUTHOR)
Crowcroft, Natasha S. (AUTHOR)
Cutts, Felicity T. (AUTHOR)
Joh, Eugene (AUTHOR)
Loisate, Stacie (AUTHOR)
Moss, William J. (AUTHOR)
Osman, Selma (AUTHOR)
Hayford, Kyla (AUTHOR)

Pokaż więcej

Źródło:

BMC Infectious Diseases. 5/31/2023, Vol. 23 Issue 1, p1-18. 18p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 19.

Tytuł:

Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection.

Autorzy:

Auerswald H; Department of Virology, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.; Virology Unit, Institut Pasteur in Cambodia, Phnom Penh 12201, Cambodia.
Kann S; Department of Virology, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
Klepsch L; Department of Virology, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
Hülsemann J; Department of Virology, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
Rudnik I; Department of Virology, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
Schreiber S; Department of Virology, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
Buchy P; Virology Unit, Institut Pasteur in Cambodia, Phnom Penh 12201, Cambodia.; GlaxoSmithKline, Vaccines R&D, Singapore 139234, Singapore.
Schreiber M; Department of Virology, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.

Pokaż więcej

Źródło:

Viruses [Viruses] 2021 Sep 29; Vol. 13 (10). Date of Electronic Publication: 2021 Sep 29.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Neutralization Tests*
Serogroup*
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*blood
Dengue/*virology
Dengue Virus/*classification
Dengue Virus/*immunology
Acute Disease ; Antibody Formation ; Cambodia ; Coinfection ; Cross Reactions ; Dengue/blood ; Humans

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 20.

Tytuł:

Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants.

Autorzy:

Zhu Y; School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.
Xiong H; School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.
Liu S; School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.
Wu D; School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.
Zhang X; Department of Microbiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China.
Shi X; Department of Microbiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China.
Qu J; Department of Microbiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China.
Chen L; Department of Microbiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China.
Liu Z; Kobilka Institute of Innovative Drug Discovery, School of Medicine, Chinese University of Hong Kong, Shenzhen 518172, China.
Peng B; Department of Microbiology Laboratory, Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China.
Zhang D; School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.; NMPA Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou 510080, China.

Pokaż więcej

Źródło:

Viruses [Viruses] 2023 Jul 17; Vol. 15 (7). Date of Electronic Publication: 2023 Jul 17.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

COVID-19*
RNA Viruses*
Humans ; SARS-CoV-2/genetics ; Antibodies, Monoclonal ; Computational Biology ; Neutralization Tests ; Antibodies, Neutralizing ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 21.

Tytuł:

A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo.

Autorzy:

Li F; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Xu W; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences and Biosafety Level 3 Laboratory, Fudan University, Shanghai, 200032, China.
Zhang X; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Department of Physiology, Naval Medical University, Shanghai, 200433, China.
Wang W; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Su S; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences and Biosafety Level 3 Laboratory, Fudan University, Shanghai, 200032, China.
Han P; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Wang H; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Xu Y; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Li M; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Fan L; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Zhang H; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Dai Q; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Lin H; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Qi X; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Liang J; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Wang X; Shanghai Longyao Biotechnology Limited, Shanghai, 201203, China.
Jiang S; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences and Biosafety Level 3 Laboratory, Fudan University, Shanghai, 200032, China.
Xie Y; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences and Biosafety Level 3 Laboratory, Fudan University, Shanghai, 200032, China. .
Lu L; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences and Biosafety Level 3 Laboratory, Fudan University, Shanghai, 200032, China. .
Yang X; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China. .; Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China. .

Pokaż więcej

Źródło:

Communications biology [Commun Biol] 2023 Jun 01; Vol. 6 (1), pp. 592. Date of Electronic Publication: 2023 Jun 01.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

COVID-19*
Animals ; Mice ; SARS-CoV-2 ; Antibodies, Viral ; Neutralization Tests ; RNA, Viral ; T-Lymphocytes

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 22.

Tytuł:

Reduced Binding between Omicron B.1.1.529 and the Human ACE2 Receptor in a Surrogate Virus Neutralization Test for SARS-CoV-2.

Autorzy:

Hoffman T; Department of Medical Biochemistry and Microbiology, Zoonosis Science Center (ZSC), Uppsala University, 752 37 Uppsala, Sweden.
Kolstad L; Department of Medical Biochemistry and Microbiology, Zoonosis Science Center (ZSC), Uppsala University, 752 37 Uppsala, Sweden.
Akaberi D; Department of Medical Biochemistry and Microbiology, Zoonosis Science Center (ZSC), Uppsala University, 752 37 Uppsala, Sweden.
Järhult JD; Department of Medical Sciences, Zoonosis Science Center (ZSC), Uppsala University, 751 85 Uppsala, Sweden.
Rönnberg B; Department of Medical Biochemistry and Microbiology, Zoonosis Science Center (ZSC), Uppsala University, 752 37 Uppsala, Sweden.
Lundkvist Å; Department of Medical Biochemistry and Microbiology, Zoonosis Science Center (ZSC), Uppsala University, 752 37 Uppsala, Sweden.

Pokaż więcej

Źródło:

Viruses [Viruses] 2023 May 30; Vol. 15 (6). Date of Electronic Publication: 2023 May 30.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Angiotensin-Converting Enzyme 2*
COVID-19*/diagnosis
Humans ; Neutralization Tests ; SARS-CoV-2/genetics ; Antibodies, Neutralizing ; Spike Glycoprotein, Coronavirus/genetics ; Antibodies, Viral

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 23.

Tytuł:

Comparing the performance of dengue virus IgG and IgG-capture enzyme-linked immunosorbent assays in seroprevalence study.

Autorzy:

Tsai JJ; Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.; Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.; School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Tsai CY; Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Lin PC; Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Chen CH; National Mosquito-Borne Diseases Control Research Center, Zhunan, Taiwan.; National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
Tsai WY; Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Dai YC; Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Lin YC; Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Pedroso C; LAPI-Laboratório de Pesquisa em Infectologia-School of Medicine, Federal University of Bahia, Salvador, Brazil.
Brites C; LAPI-Laboratório de Pesquisa em Infectologia-School of Medicine, Federal University of Bahia, Salvador, Brazil.
Wang WK; Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA. .

Pokaż więcej

Źródło:

BMC infectious diseases [BMC Infect Dis] 2023 May 08; Vol. 23 (1), pp. 301. Date of Electronic Publication: 2023 May 08.

Typ publikacji:

Journal Article

MeSH Terms:

Dengue Virus*
Zika Virus*
Zika Virus Infection*
Humans ; Seroepidemiologic Studies ; Enzyme-Linked Immunosorbent Assay ; Neutralization Tests ; Immunoglobulin G

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 24.

Tytuł:

Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4.

Autorzy:

Schuele C; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Schmeisser F; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Orr M; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Meseda CA; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Vasudevan A; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Wang W; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Weiss CD; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Woerner A; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Atukorale VN; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Pedro CL; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Weir JP; Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.

Pokaż więcej

Źródło:

Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2023 May; Vol. 17 (5), pp. e13152.

Typ publikacji:

Journal Article

MeSH Terms:

Influenza, Human*
Influenza A Virus, H5N1 Subtype*
Influenza Vaccines*
Influenza A virus*
Influenza A Virus, H5N8 Subtype*
Humans ; Animals ; Mice ; Antibodies, Monoclonal ; Antibodies, Neutralizing ; Hemagglutinins ; Antibodies, Viral ; Neutralization Tests ; Hemagglutinin Glycoproteins, Influenza Virus ; Epitopes/chemistry ; Mice, Inbred BALB C

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 25.

Tytuł:

Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera.

Autorzy:

Kruglova N; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology RAS, 119334 Moscow, Russia.
Siniavin A; N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Department of Molecular Neuroimmune Signalling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Gushchin V; N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Mazurov D; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology RAS, 119334 Moscow, Russia.

Pokaż więcej

Źródło:

Viruses [Viruses] 2021 Jun 12; Vol. 13 (6). Date of Electronic Publication: 2021 Jun 12.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Convalescence*
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*blood
Neutralization Tests/*methods
SARS-CoV-2/*immunology
Genes, Reporter/genetics ; HEK293 Cells ; Humans ; Neutralization Tests/standards ; SARS-CoV-2/genetics

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 26.

Tytuł:

Predicting the presence and titre of rabies virus-neutralizing antibodies from low-volume serum samples in low-containment facilities.

Autorzy:

Meza DK; Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.; Medical Research Council, University of Glasgow Centre for Virus Research, Glasgow, UK.
Broos A; Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.; Medical Research Council, University of Glasgow Centre for Virus Research, Glasgow, UK.
Becker DJ; Department of Biology, Indiana University, Bloomington, IN, USA.
Behdenna A; Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Willett BJ; Medical Research Council, University of Glasgow Centre for Virus Research, Glasgow, UK.
Viana M; Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Streicker DG; Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.; Medical Research Council, University of Glasgow Centre for Virus Research, Glasgow, UK.

Pokaż więcej

Źródło:

Transboundary and emerging diseases [Transbound Emerg Dis] 2021 May; Vol. 68 (3), pp. 1564-1576. Date of Electronic Publication: 2020 Sep 23.

Typ publikacji:

Journal Article

MeSH Terms:

Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
Dog Diseases/*blood
Neutralization Tests/*veterinary
Rabies/*veterinary
Rabies virus/*isolation & purification
Animals ; Dogs ; Green Fluorescent Proteins/chemistry ; Neutralization Tests/instrumentation ; Rabies/blood

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 27.

Tytuł:

Immuno-Colorimetric Neutralization Test: A Surrogate for Widely Used Plaque Reduction Neutralization Tests in Public Health Virology.

Autorzy:

Vaidya, Sunil R. (AUTHOR)

Pokaż więcej

Źródło:

Viruses (1999-4915). Apr2023, Vol. 15 Issue 4, p939. 13p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 28.

Tytuł:

Recent advances in diagnostic approaches for orf virus.

Autorzy:

Pang, Feng (AUTHOR)
Long, Qinqin (AUTHOR)

Pokaż więcej

Źródło:

Applied Microbiology & Biotechnology. Mar2023, Vol. 107 Issue 5/6, p1515-1523. 9p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 29.

Tytuł:

Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years.

Autorzy:

Gholami, Fatemeh (AUTHOR)
Hamidi Farahani, Ramin (AUTHOR)
Karimi Rahjerdi, Ahmad (AUTHOR)
Ahi, Mohammadreza (AUTHOR)
Sheidaei, Ali (AUTHOR)
Gohari, Kimiya (AUTHOR)
Rahimi, Zahra (AUTHOR)
Ansarifar, Akram (AUTHOR)
Basiri, Pouria (AUTHOR)
Moradi, Milad (AUTHOR)
Jahangiri, Arash (AUTHOR)
Naderi, Kosar (AUTHOR)
Ghasemi, Soheil (AUTHOR)
Khatami, Pezhman (AUTHOR)
Honari, Mohsen (AUTHOR)
Khodaverdloo, Samane (AUTHOR)
Shooshtari, Mohammad (AUTHOR)
Mehr Azin, Hajar (AUTHOR)
Moradi, Sohrab (AUTHOR)
Shafaghi, Batool (AUTHOR)

Pokaż więcej

Źródło:

BMC Infectious Diseases. 2/24/2023, Vol. 23 Issue 1, p1-9. 9p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 30.

Tytuł:

Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study.

Autorzy:

Jiang, Congjun (AUTHOR)
Zhou, Huan (AUTHOR)
Zhang, Wanlu (AUTHOR)
Xia, Yu (AUTHOR)
Li, Baiyong (AUTHOR)
Ni, Xiang (AUTHOR)
Wang, Guoqin (AUTHOR)
Zhang, Wenhui (AUTHOR)
Chen, Benchao (AUTHOR)
He, Zhimei (AUTHOR)
Zhang, Min (AUTHOR)
Chen, Rui (AUTHOR)
Jin, Hongzhong (AUTHOR)
Deng, Liehua (AUTHOR)

Pokaż więcej

Źródło:

Dermatology & Therapy. Feb2023, Vol. 13 Issue 2, p555-567. 13p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 31.

Tytuł:

Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers.

Autorzy:

Mouna, Lina (AUTHOR)
Razazian, Mehdi (AUTHOR)
Duquesne, Sandra (AUTHOR)
Roque-Afonso, Anne-Marie (AUTHOR)
Vauloup-Fellous, Christelle (AUTHOR)

Pokaż więcej

Źródło:

Viruses (1999-4915). Feb2023, Vol. 15 Issue 2, p426. 11p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 32.

Tytuł:

SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays.

Autorzy:

Walker GJ; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Naing Z; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia.
Ospina Stella A; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Yeang M; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia.
Caguicla J; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia.
Ramachandran V; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia.
Isaacs SR; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia.
Agapiou D; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Bull RA; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Stelzer-Braid S; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Daly J; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia.
Gosbell IB; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia.; School of Medicine, Western Sydney University, Penrith, NSW 2747, Australia.
Hoad VC; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia.
Irving DO; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia.; Faculty of Health, University of Technology, Sydney, NSW 2007, Australia.
Pink JM; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia.
Turville S; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Kelleher AD; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Rawlinson WD; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; School of Biotechnology and Biomolecular Sciences, Faculty of Science, University of New South Wales, Sydney, NSW 2052, Australia.

Pokaż więcej

Źródło:

Viruses [Viruses] 2021 Feb 04; Vol. 13 (2). Date of Electronic Publication: 2021 Feb 04.

Typ publikacji:

Journal Article

MeSH Terms:

COVID-19 Serological Testing*
Enzyme-Linked Immunosorbent Assay*
Neutralization Tests*
Antibodies, Viral/*blood
COVID-19/*immunology
SARS-CoV-2/*immunology
COVID-19/diagnosis ; Humans ; Immunoglobulin A/blood ; Immunoglobulin G/blood ; ROC Curve ; Sensitivity and Specificity

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 33.

Tytuł:

Serological Survey for Three Canine Viruses in Brazilian Wild Carnivores: Antibodies Against Canine Viruses in Wild Carnivores.

Autorzy:

Lavorente, Fernanda Louise Pereira (AUTHOR)
Spera, Caroline Giuseppa (AUTHOR)
Miyabe, Flavia Megumi (AUTHOR)
Lorenzetti, Elis (AUTHOR)
Fritzen, Juliana Torres Tomazi (AUTHOR)
Alfieri, Amauri Alcindo (AUTHOR)
Alfieri, Alice Fernandes (AUTHOR)

Pokaż więcej

Temat:

*Carnivorous animals
Immunoglobulins
Neutralization tests
Canine distemper virus
Hemagglutination tests
Canine parvovirus

Źródło:

EcoHealth. Dec2023, Vol. 20 Issue 4, p349-354. 6p.

Czasopismo naukowe

• na półce

Szczegóły

Skocz do pozycji: 34.

Tytuł:

Performance evaluation of newly developed surrogate virus neutralization tests for detecting neutralizing antibodies against SARS-CoV-2.

Autorzy:

Kweon OJ; Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Bae JY; Department of Microbiology, Institute for Viral Diseases, Vaccine Innovation Center, College of Medicine, Korea University, Seoul, Republic of Korea.
Lim YK; Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Choi Y; Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Lee S; Department of Microbiology, Institute for Viral Diseases, Vaccine Innovation Center, College of Medicine, Korea University, Seoul, Republic of Korea.
Park MS; Department of Microbiology, Institute for Viral Diseases, Vaccine Innovation Center, College of Medicine, Korea University, Seoul, Republic of Korea.
Suh IB; Department of Laboratory Medicine, College of Medicine, Kangwon National University, Chuncheon-si, Republic of Korea.
Kim H; Department of Laboratory Medicine, College of Medicine, Kangwon National University, Chuncheon-si, Republic of Korea.
Jee YS; Department of Laboratory Medicine, College of Medicine, Kangwon National University, Chuncheon-si, Republic of Korea.
Lee MK; Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2023 Mar 27; Vol. 13 (1), pp. 4961. Date of Electronic Publication: 2023 Mar 27.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

SARS-CoV-2*
COVID-19*/diagnosis
Animals ; Neutralization Tests ; Antibodies, Neutralizing ; Serologic Tests ; Callitrichinae ; Antibodies, Viral

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 35.

Tytuł:

Peptide enzyme-linked immunosorbent assay (pELISA) as a possible alternative to the neutralization test for evaluating the immune response to IBV vaccine.

Autorzy:

Wu Q; Key Laboratory of Avian Preventive Medicine, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.; Jiangsu Key Lab of Zoonosis, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.
Lin Z; Key Laboratory of Avian Preventive Medicine, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.; Jiangsu Key Lab of Zoonosis, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.
Wu J; Key Laboratory of Avian Preventive Medicine, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.; Jiangsu Key Lab of Zoonosis, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.
Qian K; Key Laboratory of Avian Preventive Medicine, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.; Jiangsu Key Lab of Zoonosis, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.; The International Joint Laboratory for Cooperation in Agriculture and Agricultural Product Safety, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.
Shao H; Key Laboratory of Avian Preventive Medicine, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.; Jiangsu Key Lab of Zoonosis, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.; The International Joint Laboratory for Cooperation in Agriculture and Agricultural Product Safety, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China.
Ye J; Key Laboratory of Avian Preventive Medicine, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .; Jiangsu Key Lab of Zoonosis, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .; The International Joint Laboratory for Cooperation in Agriculture and Agricultural Product Safety, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .; Ministry of Education Key Lab for Avian Preventive Medicine, Yangzhou University, No. 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .
Qin A; Key Laboratory of Avian Preventive Medicine, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .; Jiangsu Key Lab of Zoonosis, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .; The International Joint Laboratory for Cooperation in Agriculture and Agricultural Product Safety, Ministry of Education, Yangzhou University, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .; Ministry of Education Key Lab for Avian Preventive Medicine, Yangzhou University, No. 12 East Wenhui Road, 225009, Yangzhou, Jiangsu, P.R. China. .

Pokaż więcej

Źródło:

BMC veterinary research [BMC Vet Res] 2021 Jan 25; Vol. 17 (1), pp. 51. Date of Electronic Publication: 2021 Jan 25.

Typ publikacji:

Journal Article

MeSH Terms:

Enzyme-Linked Immunosorbent Assay*/methods
Neutralization Tests*/methods
Coronavirus Infections/*prevention & control
Infectious bronchitis virus/*immunology
Poultry Diseases/*prevention & control
Animals ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Chickens/immunology ; Chickens/virology ; Coronavirus Infections/immunology ; Poultry Diseases/immunology ; Poultry Diseases/virology ; Reproducibility of Results ; Sensitivity and Specificity

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 36.

Tytuł:

Seroprevalence of Toscana Virus and Sandfly Fever Sicilian Virus in European Bat Colonies Measured Using a Neutralization Test.

Autorzy:

Ayhan N; Unité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, France.; UR7310, Laboratoire de Virologie, Université de Corse-Inserm, 20250 Corte, France.
López-Roig M; Department of Evolutionary Biology, Ecology and Environmental Sciences, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain.; Biodiversity Research Institute, University of Barcelona, 08028 Barcelona, Spain.
Monastiri A; Department of Evolutionary Biology, Ecology and Environmental Sciences, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain.
Charrel RN; Unité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, France.
Serra-Cobo J; Department of Evolutionary Biology, Ecology and Environmental Sciences, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain.; Biodiversity Research Institute, University of Barcelona, 08028 Barcelona, Spain.

Pokaż więcej

Źródło:

Viruses [Viruses] 2021 Jan 11; Vol. 13 (1). Date of Electronic Publication: 2021 Jan 11.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Neutralization Tests*/methods
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
Chiroptera/*immunology
Chiroptera/*virology
Phlebotomus Fever/*epidemiology
Phlebotomus Fever/*transmission
Sandfly fever Naples virus/*immunology
Animals ; Geography ; Phlebotomus Fever/immunology ; Sandfly fever Naples virus/isolation & purification ; Seroepidemiologic Studies ; Spain/epidemiology

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 37.

Tytuł:

Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT).

Autorzy:

Winichakoon, Poramed (AUTHOR)
Wipasa, Jiraprapa (AUTHOR)
Chawansuntati, Kriangkrai (AUTHOR)
Salee, Parichat (AUTHOR)
Sudjaritruk, Tavitiya (AUTHOR)
Yasri, Saowaluck (AUTHOR)
khamwan, Chantana (AUTHOR)
Peerakam, Rungnapa (AUTHOR)
Dankai, Dararat (AUTHOR)
Chaiwarith, Romanee (AUTHOR)

Pokaż więcej

Źródło:

Scientific Reports. 1/2/2023, Vol. 13 Issue 1, p1-9. 9p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 38.

Tytuł:

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19.

Autorzy:

Kirste, Imke (AUTHOR)
Hortsch, Sayuri (AUTHOR)
Grunert, Veit Peter (AUTHOR)
Legault, Holly (AUTHOR)
Maglinao, Maha (AUTHOR)
Eichenlaub, Udo (AUTHOR)
Kashlan, Basel (AUTHOR)
Pajon, Rolando (AUTHOR)
Jochum, Simon (AUTHOR)

Pokaż więcej

Źródło:

Infectious Diseases & Therapy. Jan2023, Vol. 12 Issue 1, p177-191. 15p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 39.

Tytuł:

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test.

Autorzy:

Marot, Stephane (AUTHOR)
Bocar Fofana, Djeneba (AUTHOR)
Flandre, Philippe (AUTHOR)
Malet, Isabelle (AUTHOR)
Zafilaza, Karen (AUTHOR)
Leducq, Valentin (AUTHOR)
Vivien, Diane (AUTHOR)
Mrabet, Sarah (AUTHOR)
Poignon, Corentin (AUTHOR)
Calvez, Vincent (AUTHOR)
Morand-Joubert, Laurence (AUTHOR)
Marcelin, Anne-Geneviève (AUTHOR)
Gozlan, Joel (AUTHOR)

Pokaż więcej

Źródło:

Life (2075-1729). Dec2022, Vol. 12 Issue 12, p2064. 11p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 40.

Tytuł:

Plaque Reduction Neutralization Test (PRNT) in the Congenital Zika Syndrome: Positivity and Associations with Laboratory, Clinical, and Imaging Characteristics.

Autorzy:

Ribeiro MRC; Department of Medicine III, Federal University of Maranhão, Praça Gonçalves Dias, 21, Centro, São Luís CEP 65020-240, MA, Brazil.
Khouri R; Laboratory of Vector-Borne Infectious Diseases, Gonçalo Moniz Institute, Fiocruz-Bahia, Rua Waldemar Falcão, 121, Candeal, Salvador CEP 40296-710, BA, Brazil.; Department of Pathology and Legal Medicine, Faculty of Medicine, Federal University of Bahia, Praça XV de Novembro, s/n-Largo do Terreiro de Jesus, Salvador CEP 40026-010, BA, Brazil.
Sousa PS; Reference Center on Neurodevelopment, Assistance and Rehabilitation of Children/NINAR- Health Secretariat of the State of Maranhão, Av. dos Holandeses, s/n, São Luís CEP 65077-357, MA, Brazil.
Branco MRFC; Department of Pathology, Federal University of Maranhão, Praça Madre Deus, 2, Madre Deus, São Luís CEP 65025-560, MA, Brazil.
Batista RFL; Department of Public Health, Federal University of Maranhão, Rua Barão de Itapary, 155, Centro, São Luís CEP 65020-070, MA, Brazil.
Costa EPF; Department of Medicine I, Federal University of Maranhão, Praça Gonçalves Dias, 21, Centro, São Luís CEP 65020-240, MA, Brazil.
Alves MTSSB; Department of Public Health, Federal University of Maranhão, Rua Barão de Itapary, 155, Centro, São Luís CEP 65020-070, MA, Brazil.
Amaral GA; Sarah Network of Neurorehabilitation Hospitals, Av. Luis Rocha, s/n, Monte Castelo, São Luís CP 65035-270, MA, Brazil.
Borges MCR; Diagnostic Imaging Department, Federal University of São Paulo, Rua Napoleão de Barros, 800, São Paulo CEP 04024-002, SP, Brazil.
Takahasi EHM; Sarah Network of Neurorehabilitation Hospitals, Av. Luis Rocha, s/n, Monte Castelo, São Luís CP 65035-270, MA, Brazil.
Gomes LN; Laboratory of Human Immunology, Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1730, Cidade Universitária, São Paulo CEP 05508-900, SP, Brazil.
Mendes AKT; Department of Public Health, Federal University of Maranhão, Rua Barão de Itapary, 155, Centro, São Luís CEP 65020-070, MA, Brazil.
Cavalcante TB; Department of Public Health, Federal University of Maranhão, Rua Barão de Itapary, 155, Centro, São Luís CEP 65020-070, MA, Brazil.
Costa LC; Department of Public Health, Federal University of Maranhão, Rua Barão de Itapary, 155, Centro, São Luís CEP 65020-070, MA, Brazil.
Félix AC; Laboratory of Virology, Institute of Tropical Medicine, University of São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 470, São Paulo CEP 05403-000, SP, Brazil.
Souza NCS; Laboratory of Virology, Institute of Tropical Medicine, University of São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 470, São Paulo CEP 05403-000, SP, Brazil.
Silva AAM; Department of Public Health, Federal University of Maranhão, Rua Barão de Itapary, 155, Centro, São Luís CEP 65020-070, MA, Brazil.

Pokaż więcej

Źródło:

Viruses [Viruses] 2020 Oct 31; Vol. 12 (11). Date of Electronic Publication: 2020 Oct 31.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Neutralization Tests*
Viral Plaque Assay*
Zika Virus Infection/*congenital
Zika Virus Infection/*diagnosis
Brazil ; Child, Preschool ; Clinical Laboratory Techniques ; Cohort Studies ; Cross Reactions ; Female ; Humans ; Infant ; Pregnancy ; Serologic Tests ; Tomography

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 41.

Tytuł:

Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV.

Autorzy:

Mosa AI; Department of Cell and Systems Biology, University of Toronto, Toronto, Canada. .
AbouHaidar MG; Department of Cell and Systems Biology, University of Toronto, Toronto, Canada.
Urbanowicz RA; Wolfson Centre for Global Virus Infections, University of Nottingham, Nottingham, UK.; School of Life Sciences, University of Nottingham, Nottingham, UK.
Tavis JE; Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, USA.
Ball JK; Wolfson Centre for Global Virus Infections, University of Nottingham, Nottingham, UK.; School of Life Sciences, University of Nottingham, Nottingham, UK.
Feld JJ; Toronto Centre for Liver Disease, Toronto General Hospital, Sandra Rotman Centre for Global Health, University of Toronto, Toronto, Canada.

Pokaż więcej

Źródło:

Virology journal [Virol J] 2020 Sep 18; Vol. 17 (1), pp. 140. Date of Electronic Publication: 2020 Sep 18.

Typ publikacji:

Journal Article

MeSH Terms:

Genotype*
Neutralization Tests*
Antibodies, Viral/*blood
Hepacivirus/*genetics
Hepatitis C/*immunology
Viral Proteins/*genetics
Viral Proteins/*immunology
Animals ; Antibodies, Neutralizing/blood ; Cross Reactions/immunology ; Epitopes, B-Lymphocyte/immunology ; Female ; Hepacivirus/chemistry ; Hepacivirus/classification ; Hepacivirus/immunology ; Hepatitis C Antibodies/blood ; Hepatitis C Antibodies/immunology ; Humans ; Mice ; Mice, Inbred BALB C

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 42.

Tytuł:

Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.

Autorzy:

Deshpande GR; Diagnostic Virology Group, Pimpri Chinchwad Municipal Corporation, Pune, Maharashtra, India.
Sapkal GN; Diagnostic Virology Group, Pimpri Chinchwad Municipal Corporation, Pune, Maharashtra, India.
Tilekar BN; Diagnostic Virology Group, Pimpri Chinchwad Municipal Corporation, Pune, Maharashtra, India.
Yadav PD; Maximum Containment Facility, ICMR-National Institute of Virology, Pune, Maharashtra, India.
Gurav Y; Epidemiology Group, ICMR-National Institute of Virology, Pune, Maharashtra, India.
Gaikwad S; Diagnostic Virology Group, Pimpri Chinchwad Municipal Corporation, Pune, Maharashtra, India.
Kaushal H; Influenza Group, ICMR-National Institute of Virology, Pune, Maharashtra, India.
Deshpande KS; Diagnostic Virology Group, Pimpri Chinchwad Municipal Corporation, Pune, Maharashtra, India.
Kaduskar O; Diagnostic Virology Group, Pimpri Chinchwad Municipal Corporation, Pune, Maharashtra, India.
Sarkale P; Maximum Containment Facility, ICMR-National Institute of Virology, Pune, Maharashtra, India.
Baradkar S; Maximum Containment Facility, ICMR-National Institute of Virology, Pune, Maharashtra, India.
Suryawanshi A; Maximum Containment Facility, ICMR-National Institute of Virology, Pune, Maharashtra, India.
Lakra R; Maximum Containment Facility, ICMR-National Institute of Virology, Pune, Maharashtra, India.
Sugunan AP; ICMR-National Institute of Virology, Kerala Unit, Alappuzha, Kerala, India.
Balakrishnan A; ICMR-National Institute of Virology, Kerala Unit, Alappuzha, Kerala, India.
Abraham P; Diagnostic Virology Group, Pimpri Chinchwad Municipal Corporation, Pune, Maharashtra, India.
Salve P; Medical Department, Pimpri Chinchwad Municipal Corporation, Pune, Maharashtra, India.

Pokaż więcej

Źródło:

The Indian journal of medical research [Indian J Med Res] 2020 Jul & Aug; Vol. 152 (1 & 2), pp. 82-87.

Typ publikacji:

Journal Article

MeSH Terms:

Neutralization Tests*
Pandemics*
Antibodies, Neutralizing/*isolation & purification
Coronavirus Infections/*blood
Pneumonia, Viral/*blood
Adolescent ; Adult ; Animals ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/blood ; Betacoronavirus/immunology ; Betacoronavirus/pathogenicity ; COVID-19 ; Child ; Chlorocebus aethiops/immunology ; Coronavirus Infections/epidemiology ; Coronavirus Infections/immunology ; Coronavirus Infections/virology ; Female ; Humans ; Immunoglobulin G/blood ; Male ; Middle Aged ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/immunology ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Vero Cells/immunology ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 43.

Tytuł:

An in vitro methodology for discovering broadly-neutralizing monoclonal antibodies.

Autorzy:

Ahmadi S; Department of Biotechnology and Biosafety, Graduate School of Natural and Applied Sciences, Eskisehir Osmangazi University, Eskisehir, Turkey.; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Pucca MB; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.; Medical School, Federal University of Roraima, Boa Vista, Roraima, Brazil.
Jürgensen JA; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Janke R; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Ledsgaard L; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Schoof EM; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Sørensen CV; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Çalışkan F; Department of Biotechnology and Biosafety, Graduate School of Natural and Applied Sciences, Eskisehir Osmangazi University, Eskisehir, Turkey.; Department of Biology, Faculty of Science and Letters, Eskisehir Osmangazi University, Eskisehir, Turkey.
Laustsen AH; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2020 Jul 01; Vol. 10 (1), pp. 10765. Date of Electronic Publication: 2020 Jul 01.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Neutralization Tests*
Antibodies, Monoclonal/*chemistry
Antibodies, Neutralizing/*chemistry
Antivenins/*chemistry
Animals ; Antigens/chemistry ; Biotechnology ; Cross Reactions/immunology ; Drug Design ; Enzyme-Linked Immunosorbent Assay ; Humans ; Immunoglobulin Fab Fragments/immunology ; In Vitro Techniques ; Inhibitory Concentration 50 ; Keratinocytes/immunology ; Mass Spectrometry ; Peptide Library ; Proteomics ; Recombinant Proteins/chemistry ; Snakes ; Venoms

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 44.

Tytuł:

Preparation and qualification of internal rabies reference standards for use in the rabies rapid fluorescent focus inhibition test.

Autorzy:

Timiryasova TM; Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA, 18370, USA. .
Hodge SA; Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA, 18370, USA.
Zheng L; Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA, 18370, USA.
Singer A; Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA, 18370, USA.
Vincent D; Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA, 18370, USA.
Rahman M; Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA, 18370, USA.
Petit C; Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA, 18370, USA.
Brown M; Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA, 18370, USA.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2020 Jun 18; Vol. 10 (1), pp. 9893. Date of Electronic Publication: 2020 Jun 18.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Neutralization Tests/*standards
Rabies/*diagnosis
Antibodies, Viral/blood ; Antibodies, Viral/immunology ; Antigen-Antibody Reactions ; Antigens, Viral/immunology ; Humans ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Limit of Detection ; Neutralization Tests/methods ; Rabies/virology ; Rabies Vaccines/immunology ; Rabies virus/immunology ; Reference Standards ; Reproducibility of Results ; Sensitivity and Specificity ; World Health Organization

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 45.

Tytuł:

Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America.

Autorzy:

Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.
Bonaparte M; Global Clinical Immunology, Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.
Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Juraska M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.
Price B; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.
Zhuang Y; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.
Shao J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Zheng L; Global Clinical Immunology, Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.
Chambonneau L; Clinical Sciences, Sanofi Pasteur, Marcy-L'Etoile, France.
Small R; Sanofi Pasteur, Orlando, Florida, United States of America.
Sridhar S; Clinical Sciences, Sanofi Pasteur, Marcy-L'Etoile, France.
DiazGranados CA; Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.
Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2020 Jun 15; Vol. 15 (6), pp. e0234236. Date of Electronic Publication: 2020 Jun 15 (Print Publication: 2020).

Typ publikacji:

Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

MeSH Terms:

Neutralization Tests*
Dengue Vaccines/*immunology
Adolescent ; Asia ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Latin America ; Male

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 46.

Tytuł:

A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern.

Autorzy:

Parray HA; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Narayanan N; Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Garg S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Rizvi ZA; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Shrivastava T; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Kushwaha S; National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India.
Singh J; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Murugavelu P; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Anantharaj A; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Mehdi F; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Raj N; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Singh S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Dandotiya J; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Lukose A; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Jamwal D; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Kumar S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Chiranjivi AK; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Dhyani S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Mishra N; Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Kumar S; ICGEB-Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
Jakhar K; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Sonar S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Panchal AK; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Tripathy MR; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Chowdhury SR; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Ahmed S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Samal S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Mani S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Bhattacharyya S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Das S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Sinha S; Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Luthra K; Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Batra G; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Sehgal D; National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India.
Medigeshi GR; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Sharma C; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Awasthi A; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Garg PK; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Nair DT; Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Kumar R; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.

Pokaż więcej

Źródło:

PLoS pathogens [PLoS Pathog] 2022 Dec 12; Vol. 18 (12), pp. e1010994. Date of Electronic Publication: 2022 Dec 12 (Print Publication: 2022).

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Angiotensin-Converting Enzyme 2*/chemistry
Antibodies, Neutralizing*/therapeutic use
COVID-19*/immunology
COVID-19*/therapy
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Animals ; Humans ; Mice ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Viral/therapeutic use ; Mice, Transgenic ; Neutralization Tests ; Spike Glycoprotein, Coronavirus/genetics

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 47.

Tytuł:

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years.

Autorzy:

Durier C; INSERM US19, Villejuif, France. .
Ninove L; Unité des Virus Émergents (UVE), Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.
Lefebvre M; Maladies Infectieuses et Tropicales, Centre de Prévention des Maladies Infectieuses et Transmissibles CHU de Nantes, INSERM CIC1413, Nantes, France.
Radenne A; Assistance Publique Hôpitaux de Paris, Unité de Recherche Clinique des Hôpitaux Universitaires Pitié Salpêtrière -Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris, France.
Desaint C; INSERM US19, Villejuif, France.; INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France.
Ropers J; Assistance Publique Hôpitaux de Paris, Unité de Recherche Clinique des Hôpitaux Universitaires Pitié Salpêtrière -Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris, France.
Bauer R; INSERM US19, Villejuif, France.
Lebbah S; Assistance Publique Hôpitaux de Paris, Unité de Recherche Clinique des Hôpitaux Universitaires Pitié Salpêtrière -Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris, France.
Carette D; INSERM US19, Villejuif, France.
Lachatre M; INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France.
Lecompte AS; Maladies Infectieuses et Tropicales, Centre de Prévention des Maladies Infectieuses et Transmissibles CHU de Nantes, INSERM CIC1413, Nantes, France.
Deplanque D; INSERM, CHU Lille, CIC 1403 - Centre d'investigation Clinique, Univ. Lille, Lille, France.
Botelho-Nevers E; Infectious Diseases Department, CIC 1408 INSERM University Hospital of Saint-Etienne, University Hospital of Saint-Etienne, Saint-Etienne, France.
Conrad A; Department Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Univ. Claude Bernard Lyon I, CNRS, UMR5308, ENS de Lyon, Univ Lyon, Lyon, France.; Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, Université Claude Bernard Lyon I, Lyon, France.
Dussol B; Centre d'Investigation Clinique 1409, Hôpital de la Conception, INSERM- Hôpitaux Universitaires de Marseille - Aix Marseille Université, Marseille, France.
Maakaroun-Vermesse Z; Centre de Vaccination CHU de Tours, Centre d'Investigation Clinique CIC 1415, INSERM, CHRU de Tours, Tours, France.
Melica G; Service d'Immunologie Clinique et Maladies Infectieuses, APHP, Hôpital Henri Mondor, Créteil, France.; Centre d'Investigation Clinique 1430 INSERM, APHP, Hôpital Henri Mondor, Créteil, France.
Nicolas JF; Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, Université Claude Bernard Lyon I, Lyon, France.; CHU Lyon-Sud, Pierre-Bénite, France.
Verdon R; Service de Maladies Infectieuses, CHU de Caen, Caen, France.; Dynamicure INSERM, UMR 1311, Normandie Univ, UNICAEN, Caen, France.
Kiladjian J; AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, CIC1427, Université Paris Cité, Paris, France.
Loubet P; VBMI, INSERM U1047, Department of Infectious and Tropical Diseases, Université de Montpellier, CHU Nîmes, Univ Montpellier, Nîmes, France.
Schmidt-Mutter C; Inserm CIC 1434, CHU Strasbourg, Strasbourg, France.
Dualé C; Centre d'Investigation Clinique (INSERM CIC1405), CHU Clermont-Ferrand, Clermont-Ferrand, France.
Ansart S; Centre d'Investigation Clinique CIC 1412, INSERM, CHU Brest, Brest, France.
Priet S; Unité des Virus Émergents (UVE), Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.
Levier A; ANRS | Emerging Infectious Diseases, Paris, France.
Molino D; INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France.
Vieillard LV; INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France.
Parfait B; Fédération des Centres de Ressources Biologiques - Plateforme de Ressources Biologiques APHP -Université de Paris, Centre de Ressources Biologiques Cochin, Hôpital Cochin, Paris, France.
Lelièvre JD; INSERM U955, Vaccine Research Institute, Créteil, France.
Tartour E; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, Paris, France.
de Lamballerie X; Unité des Virus Émergents (UVE), Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.
Launay O; INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France.

Pokaż więcej

Corporate Authors:

ANRS0002S CoviCompareP Group
AP-HP CoviCompareM Group
Biological resource centers
Laboratories
Trial coordination
Sponsor
Scientific Committee

Źródło:

Scientific reports [Sci Rep] 2022 Nov 27; Vol. 12 (1), pp. 20373. Date of Electronic Publication: 2022 Nov 27.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Viral Vaccines*
COVID-19*/prevention & control
Humans ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing ; SARS-CoV-2/genetics ; Neutralization Tests ; Antibodies, Viral ; RNA, Messenger ; Vaccination

SCR Protocol:

COVID-19 vaccine booster shot

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 48.

Tytuł:

Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations.

Autorzy:

Jacobsen H; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Strengert M; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.; TWINCORE, Centre for Experimental and Clinical Infection Research, Joint Venture of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany.
Maaß H; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Ynga Durand MA; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Katzmarzyk M; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Kessel B; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Harries M; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Rand U; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Abassi L; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Kim Y; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Lüddecke T; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Metzdorf K; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Hernandez P; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Ortmann J; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Heise JK; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Castell S; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Gornyk D; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Glöckner S; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Melhorn V; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Kemmling Y; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Lange B; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.; German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Braunschweig, Germany.
Dulovic A; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Marsall P; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Häring J; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Junker D; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Schneiderhan-Marra N; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Hoffmann M; Deutsches Primatenzentrum, Leibniz-Institut Für Primatenforschung, Göttingen, Germany.; Faculty of Biology and Psychology, Georg-August-University, Göttingen, Germany.
Pöhlmann S; Deutsches Primatenzentrum, Leibniz-Institut Für Primatenforschung, Göttingen, Germany.; Faculty of Biology and Psychology, Georg-August-University, Göttingen, Germany.
Krause G; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany. .; TWINCORE, Centre for Experimental and Clinical Infection Research, Joint Venture of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany. .; German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Braunschweig, Germany. .
Cicin-Sain L; Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany. .; German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Braunschweig, Germany. .; Centre for Individualized Infection Medicine (CIIM), Joint Venture of Helmholtz Centre for Infection Research and Medical School Hannover, Inhoffenstraße 7, 38124, Braunschweig, Germany. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2022 Nov 18; Vol. 12 (1), pp. 19858. Date of Electronic Publication: 2022 Nov 18.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

SARS-CoV-2*/genetics
COVID-19*/prevention & control
Humans ; Neutralization Tests ; Antibodies, Viral ; COVID-19 Vaccines ; RNA, Messenger ; Ad26COVS1 ; BNT162 Vaccine ; ChAdOx1 nCoV-19 ; Vaccination

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 49.

Tytuł:

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.

Autorzy:

Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Pinto D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
De Marco A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Benigni F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Zatta F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bassi J; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Addetia A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Stewart C; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Giurdanella M; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Saliba C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Guarino B; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Schmid MA; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Dang HV; Vir Biotechnology, San Francisco, CA, USA.
Hauser K; Vir Biotechnology, San Francisco, CA, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA, USA.
Rivera W; Vir Biotechnology, San Francisco, CA, USA.
Schnell G; Vir Biotechnology, San Francisco, CA, USA.
Rajesh A; Vir Biotechnology, San Francisco, CA, USA.
Zhou J; Vir Biotechnology, San Francisco, CA, USA.
Farhat N; Vir Biotechnology, San Francisco, CA, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
Noack J; Vir Biotechnology, San Francisco, CA, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
Janer J; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Abdelnabi R; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Maes P; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.
Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
de Melo GD; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Kergoat L; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Bourhy H; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Soriaga L; Vir Biotechnology, San Francisco, CA, USA.
Purcell LA; Vir Biotechnology, San Francisco, CA, USA.
Snell G; Vir Biotechnology, San Francisco, CA, USA.
Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Lanzavecchia A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Piccoli L; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Pizzuto MS; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Corti D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.

Pokaż więcej

Źródło:

Science (New York, N.Y.) [Science] 2022 Nov 11; Vol. 378 (6620), pp. 619-627. Date of Electronic Publication: 2022 Oct 20.

Typ publikacji:

Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

MeSH Terms:

Antibodies, Neutralizing*/immunology
Antibodies, Viral*/immunology
Antibody Formation*
COVID-19*/immunology
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*
Immune Evasion*
Humans ; Neutralization Tests ; Immunologic Memory ; Memory B Cells/immunology

SCR Organism:

SARS-CoV-2 variants

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 50.

Tytuł:

Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.

Autorzy:

Zedan HT; Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.; Biomedical Research Center, Qatar University, P.O. Box 2713, Doha, Qatar.
Yassine HM; Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar. .; Biomedical Research Center, Qatar University, P.O. Box 2713, Doha, Qatar. .
Al-Sadeq DW; Biomedical Research Center, Qatar University, P.O. Box 2713, Doha, Qatar.; College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
Liu N; Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China.
Qotba H; Department of Clinical Research, Primary Health Care Centers, Doha, Qatar.
Nicolai E; Department of Experimental Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.
Pieri M; Department of Experimental Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.
Bernardini S; Department of Experimental Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.; Clinical Biochemistry, Tor Vergata University Hospital, 00133, Rome, Italy.
Abu-Raddad LJ; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar.; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar.; Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, USA.
Nasrallah GK; Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar. .; Biomedical Research Center, Qatar University, P.O. Box 2713, Doha, Qatar. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2022 Nov 08; Vol. 12 (1), pp. 19020. Date of Electronic Publication: 2022 Nov 08.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

SARS-CoV-2*
COVID-19*/diagnosis
Humans ; RNA, Viral ; Antibodies, Viral ; Neutralization Tests ; Enzyme-Linked Immunosorbent Assay ; Antibodies, Neutralizing

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły